Axcella Health Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
840 Memorial Drive, Third Floor, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Pronutria Biosciences, Inc. (to 2/24/2016)
Latest financial report
10-Q - Q2 2023 - Aug 3, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 113 % -76.9%
Debt-to-equity -1.56K % -1118%
Return On Equity 3.92K %
Return On Assets -269 % -123%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 73.7M shares +40%
Common Stock, Shares, Outstanding 73.7M shares +40%
Entity Public Float 67.8M USD -32.8%
Common Stock, Value, Issued 74K USD +39.6%
Weighted Average Number of Shares Outstanding, Basic 73.7M shares +40%
Weighted Average Number of Shares Outstanding, Diluted 73.7M shares +40%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 29.2M USD -44.9%
General and Administrative Expense 12.3M USD -31.6%
Operating Income (Loss) -45.8M USD +35.6%
Nonoperating Income (Expense) -2.47M USD +11.8%
Net Income (Loss) Attributable to Parent -48.2M USD +34.7%
Earnings Per Share, Basic -0.73 USD/shares +58%
Earnings Per Share, Diluted -0.73 USD/shares +58%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.88M USD -73.9%
Marketable Securities, Current 0 USD -100%
Cash, Cash Equivalents, and Short-term Investments 44.4M USD -43.7%
Assets, Current 9.27M USD -79.9%
Property, Plant and Equipment, Net 15K USD -98.4%
Operating Lease, Right-of-Use Asset 2.35M USD
Other Assets, Noncurrent 0 USD -100%
Assets 9.28M USD -81.4%
Accounts Payable, Current 8.4M USD +110%
Employee-related Liabilities, Current 470K USD -81.3%
Accrued Liabilities, Current 1.75M USD -78.7%
Liabilities, Current 11.5M USD -32.8%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 11.5M USD -71.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -426M USD -12.8%
Stockholders' Equity Attributable to Parent -2.26M USD -124%
Liabilities and Equity 9.28M USD -81.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.8M USD +75.2%
Net Cash Provided by (Used in) Financing Activities -27K USD -100%
Net Cash Provided by (Used in) Investing Activities 525K USD -96%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 74.1M shares +39.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.61M USD -121%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.88M USD -73.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 122M USD +23.7%
Deferred Tax Assets, Gross 122M USD +23.7%
Operating Lease, Liability 1.39M USD -51.8%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -48.2M USD +34.8%
Lessee, Operating Lease, Liability, to be Paid 1.45M USD -53.9%
Property, Plant and Equipment, Gross 87K USD -98.1%
Operating Lease, Liability, Current 1.39M USD -7.08%
Lessee, Operating Lease, Liability, to be Paid, Year Two 580K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 580K USD -66.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 59K USD -77.1%
Deferred Tax Assets, Operating Loss Carryforwards 89.3M USD +8.76%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.39M USD -100%
Additional Paid in Capital 423M USD +9.46%
Operating Leases, Future Minimum Payments, Due in Two Years 580K USD -66.3%
Depreciation, Depletion and Amortization 0 USD -100%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 1.72M USD +2.99%
Share-based Payment Arrangement, Expense 2.45M USD -53.3%
Operating Leases, Future Minimum Payments Due 2.3M USD -42.1%